Table 1. Incidence of solicited local and general symptoms during the 7-d post-vaccination period following two doses of HZ/su (total vaccinated cohort).
| Young adults (18–30 y) (20 administered doses) |
Older adults (50–69 y) (19 administered doses) |
||||||
|---|---|---|---|---|---|---|---|
| Symptoms | n | % | 95% CI | n | % | 95% CI | |
| Local symptoms | |||||||
| Pain | Any | 20 | 100 | 83; 100 | 17 | 90 | 66; 99 |
| Grade 3 | 4 | 20 | 5; 44 | 1 | 5 | 0; 26 | |
| Redness | Any | 3 | 15 | 3; 38 | 8 | 42 | 20; 67 |
| Grade 3 | 0 | 0 | 0; 17 | 5 | 26 | 9; 52 | |
| Swelling | Any | 7 | 35 | 15; 60 | 9 | 47 | 24; 72 |
| Grade 3 | 0 | 0 | 0; 17 | 2 | 11 | 1; 34 | |
| General symptoms | |||||||
| Fatigue | Any | 20 | 100 | 83; 100 | 19 | 100 | 82; 100 |
| Grade 3 | 6 | 30 | 11; 55 | 2 | 11 | 1; 34 | |
| Gastrointestinal | Any | 6 | 30 | 11; 55 | 6 | 32 | 12; 57 |
| Grade 3 | 0 | 0 | 0; 17 | 0 | 0 | 0; 18 | |
| Headache | Any | 14 | 70 | 45; 89 | 11 | 58 | 33; 80 |
| Grade 3 | 5 | 25 | 8; 50 | 1 | 5 | 0; 26 | |
| Myalgia | Any | 19 | 95 | 75; 100 | 16 | 84 | 60; 97 |
| Grade 3 | 4 | 20 | 5; 44 | 0 | 0 | 0; 18 | |
| Temperature/(Orally) (°C) | Any | 10 | 50 | 27; 73 | 10 | 53 | 28; 76 |
| Grade 3 | 0 | 0 | 0; 17 | 0 | 0 | 0; 18 | |
n (%), number (percentage) of doses followed by at least one symptom; 95% CI, Exact 95% confidence interval